Chronic Respiratory Disease最新文献

筛选
英文 中文
The experience of caregiver burden when being next of kin to a person with severe chronic obstructive pulmonary disease: A qualitative study. 重度慢性阻塞性肺疾病患者的近亲照顾者负担:一项定性研究
IF 4.1 3区 医学
Chronic Respiratory Disease Pub Date : 2023-01-01 DOI: 10.1177/14799731231168897
Helena Johansson, Carina Berterö, Lise-Lotte Jonasson, Katarina Berg
{"title":"The experience of caregiver burden when being next of kin to a person with severe chronic obstructive pulmonary disease: A qualitative study.","authors":"Helena Johansson,&nbsp;Carina Berterö,&nbsp;Lise-Lotte Jonasson,&nbsp;Katarina Berg","doi":"10.1177/14799731231168897","DOIUrl":"https://doi.org/10.1177/14799731231168897","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is an inflammatory and irreversible lung disease. For next of kin caregiver burden can be a consequence of the situation of being close to a person affected by a chronic disease and in need of help. When there is an imbalance between stressors and resources to cope with the situation, caregiver burden emerges. Knowledge is sparse about how the caregiver burden is experienced by the next of kin. Therefore, the aim of this study is to identify and describe the caregiver burden experienced by next of kin of persons with severe COPD.</p><p><strong>Method: </strong>Qualitative interviews with 21 next of kin were conducted. Thematic analysis was used in accordance with the six steps of Braun and Clarke.</p><p><strong>Results: </strong>The next of kin experience caregiver burden as 1) changed roles in daily life 2) putting life on hold 3) to stand aside. The next of kin are in need of support to manage daily life.</p><p><strong>Conclusions: </strong>The caregiver burden affect the next of kin physically and emotionally. To prevent advance consequences, person-centered care can be used to support the next of kin in the situation.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"20 ","pages":"14799731231168897"},"PeriodicalIF":4.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/53/10.1177_14799731231168897.PMC10107968.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9728837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Impact of cognitive capacity on physical performance in chronic obstructive pulmonary disease patients: A scoping review. 慢性阻塞性肺疾病患者认知能力对身体表现的影响:范围综述
IF 3.5 3区 医学
Chronic Respiratory Disease Pub Date : 2023-01-01 DOI: 10.1177/14799731231163874
Peter Rassam, Eli M Pazzianotto-Forti, Umi Matsumura, Ani Orchanian-Cheff, Saina Aliabadi, Manjiri Kulkarni, Rachel L Fat Fur, Antenor Rodrigues, Daniel Langer, Dmitry Rozenberg, W Darlene Reid
{"title":"Impact of cognitive capacity on physical performance in chronic obstructive pulmonary disease patients: A scoping review.","authors":"Peter Rassam, Eli M Pazzianotto-Forti, Umi Matsumura, Ani Orchanian-Cheff, Saina Aliabadi, Manjiri Kulkarni, Rachel L Fat Fur, Antenor Rodrigues, Daniel Langer, Dmitry Rozenberg, W Darlene Reid","doi":"10.1177/14799731231163874","DOIUrl":"10.1177/14799731231163874","url":null,"abstract":"<p><p><b>Background:</b> Chronic obstructive pulmonary disease (COPD) is often accompanied by impaired cognitive and physical function. However, the role of cognitive function on motor control and purposeful movement is not well studied. The aim of the review was to determine the impact of cognition on physical performance in COPD. <b>Methods:</b> Scoping review methods were performed including searches of the databases: MEDLINE, EMBASE, Cochrane Systematic Reviews, Cochrane (CENTRAL), APA PsycINFO, and CINAHL. Two reviewers independently assessed articles for inclusion, data abstraction, and quality assessment. <b>Results:</b> Of 11,252 identified articles, 44 met the inclusion criteria. The review included 5743 individuals with COPD (68% male) with the forced expiratory volume in one second range of 24-69% predicted. Cognitive scores correlated with strength, balance, and hand dexterity, while 6-min walk distance (<i>n</i> = 9) was usually similar among COPD patients with and without cognitive impairment. In 2 reports, regression analyses showed that delayed recall and the trail making test were associated with balance and handgrip strength, respectively. Dual task studies (<i>n</i> = 5) reported impaired balance or gait in COPD patients compared to healthy adults. Cognitive or physical Interventions (<i>n</i> = 20) showed variable improvements in cognition and exercise capacity. <b>Conclusions:</b> Cognition in COPD appears to be more related to balance, hand, and dual task function, than exercise capacity.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"20 ","pages":"14799731231163874"},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/86/10.1177_14799731231163874.PMC10087654.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9643639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis. 同时评估非囊性纤维化支气管扩张患者T2高内型呼出一氧化氮分数和血液嗜酸性粒细胞计数。
IF 4.1 3区 医学
Chronic Respiratory Disease Pub Date : 2023-01-01 DOI: 10.1177/14799731231210559
Fengjia Chen, Zhimin Zeng, Xinyan Huang, Yangli Liu
{"title":"Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis.","authors":"Fengjia Chen,&nbsp;Zhimin Zeng,&nbsp;Xinyan Huang,&nbsp;Yangli Liu","doi":"10.1177/14799731231210559","DOIUrl":"10.1177/14799731231210559","url":null,"abstract":"<p><strong>Objective: </strong>Recently, a type 2 inflammation (T2) high endotype in bronchiectasis was identified. The fraction of exhaled nitric oxide (FeNO) and blood eosinophil count (BEC) are recognized as representative biomarkers of T2 inflammation. Herein, we investigate the clinical characteristics of T2-high endotype in non-cystic fibrosis bronchiectasis patients classified by FeNO and BEC.</p><p><strong>Methods: </strong>This retrospective study included 164 bronchiectasis patients treated in the First Affiliated Hospital of Sun Yat-sen University from December 2017 to July 2022. Clinical characteristics were analyzed after classifying patients into four groups according to T2 inflammation biomarkers (FeNO ≥25 ppb; BEC ≥200/µL).</p><p><strong>Results: </strong>Among the 164 bronchiectasis patients, 35.3% (58/164) presented with high FeNO, 30.5% (50/164) presented with high BEC, and 10.4% (17/164) had high FeNO and BEC. Patients with high FeNO and low BEC presented with better lung function, fewer affected lobes, and lower dyspnea prevalence compared with the three other groups. Moreover, decreased FeNO, instead of decreased BEC, is revealed to be an independent predictor for disease severity and airflow obstruction in bronchiectasis.</p><p><strong>Conclusions: </strong>Simultaneous evaluation of FeNO and BEC proposed different endotypes of bronchiectasis established that patients with low BEC and high FeNO had better lung function, fewer affected lobes, lower dyspnea prevalence, and less disease severity. This result will contribute to a more comprehensive assessment of the disease severity and lead to more precise treatment of T2 inflammation in bronchiectasis patients.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"20 ","pages":"14799731231210559"},"PeriodicalIF":4.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies to deliver smoking cessation interventions during targeted lung health screening - a systematic review and meta-analysis. 在有针对性的肺部健康筛查期间提供戒烟干预措施的策略——一项系统回顾和荟萃分析。
IF 4.1 3区 医学
Chronic Respiratory Disease Pub Date : 2023-01-01 DOI: 10.1177/14799731231183446
Parris J Williams, Keir Ej Philip, Saeed M Alghamdi, Alexis M Perkins, Sara C Buttery, Michael I Polkey, Anthony A Laverty, Nicholas S Hopkinson
{"title":"Strategies to deliver smoking cessation interventions during targeted lung health screening - a systematic review and meta-analysis.","authors":"Parris J Williams,&nbsp;Keir Ej Philip,&nbsp;Saeed M Alghamdi,&nbsp;Alexis M Perkins,&nbsp;Sara C Buttery,&nbsp;Michael I Polkey,&nbsp;Anthony A Laverty,&nbsp;Nicholas S Hopkinson","doi":"10.1177/14799731231183446","DOIUrl":"https://doi.org/10.1177/14799731231183446","url":null,"abstract":"<p><strong>Introduction: </strong>Lung cancer screening presents an important teachable moment to promote smoking cessation, but the most effective strategy to deliver support in this context remains to be established.</p><p><strong>Methods: </strong>We undertook a systematic review and meta-analysis of smoking cessation interventions delivered during lung health screening, published prior to 20/07/2022 MEDLINE, PsychINFO, CENTRAL, EMBASE, CINAHL and Scopus databases. Two reviewers screened titles, and abstracts, four reviewed each full text using prespecified criteria, extracted relevant data, assessed risk of bias and confidence in findings using the GRADE criteria. The review was registered prospectively on PROSPERO (CRD42021242431).</p><p><strong>Results: </strong>10 randomised controlled trials and three observational studies with a control group were identified. Meta-analysis of nine RCTs demonstrated that smoking cessation interventions delivered during lung screening programmes increased quit rates compared to usual care (odds ratios: 2.01, 95%: 1.49-2.72 <i>p</i> < 0.001). Six RCTs using intensive (≥3 behavioural counselling sessions) interventions demonstrated greater quit rates compared to usual care (OR: 2.11, 95% CI 1.53-2.90, <i>p</i> < 0.001). A meta-analysis of two RCTs found intensive interventions were more effective than non-intensive (OR: 2.07, 95%CI 1.26-3.40 <i>p</i> = 0.004), Meta-analysis of two RCTs of non-intensive interventions (≤2 behavioural counselling sessions or limited to online information audio take home materials such as pamphlets) did not show a higher quit rate than usual care (OR: 0.90, 95% CI 0.39-2.08 <i>p</i> = 0.80).</p><p><strong>Discussion: </strong>Moderate quality evidence supports smoking cessation interventions delivered within a lung screening setting compared to usual care, with high-quality evidence that more intensive interventions are likely to be most effective.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"20 ","pages":"14799731231183446"},"PeriodicalIF":4.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/00/10.1177_14799731231183446.PMC10286547.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9699432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Disparities in self-reported healthcare access for airways disease in British Columbia, Canada, during the COVID-19 pandemic. Insights from a survey co-developed with people living with asthma and chronic obstructive pulmonary disease. 2019冠状病毒病大流行期间,加拿大不列颠哥伦比亚省呼吸道疾病患者自我报告的医疗服务可及性差异来自与哮喘和慢性阻塞性肺病患者共同开展的一项调查的见解。
IF 4.1 3区 医学
Chronic Respiratory Disease Pub Date : 2023-01-01 DOI: 10.1177/14799731231172518
Aneisha Collins-Fairclough, Prabjit Barn, A J Hirsch-Allen, Karen Rideout, Erin M Shellington, Winnie Lo, Tony Lanier, Jim Johnson, Adam Butcher, Sian-Hoe Cheong, Carmen Rempel, Nardia Strydom, Pat G Camp, Christopher Carlsten
{"title":"Disparities in self-reported healthcare access for airways disease in British Columbia, Canada, during the COVID-19 pandemic. Insights from a survey co-developed with people living with asthma and chronic obstructive pulmonary disease.","authors":"Aneisha Collins-Fairclough,&nbsp;Prabjit Barn,&nbsp;A J Hirsch-Allen,&nbsp;Karen Rideout,&nbsp;Erin M Shellington,&nbsp;Winnie Lo,&nbsp;Tony Lanier,&nbsp;Jim Johnson,&nbsp;Adam Butcher,&nbsp;Sian-Hoe Cheong,&nbsp;Carmen Rempel,&nbsp;Nardia Strydom,&nbsp;Pat G Camp,&nbsp;Christopher Carlsten","doi":"10.1177/14799731231172518","DOIUrl":"https://doi.org/10.1177/14799731231172518","url":null,"abstract":"<p><p>Patients' perspectives on the impact of the COVID-19 pandemic on their access to asthma and COPD healthcare could inform better, more equitable care delivery. We demonstrate this topic using British Columbia (BC), Canada, where the impact of the pandemic has not been described. We co-designed a cross-sectional survey with patient partners and administered it to a convenience sample of people living with asthma and COPD in BC between September 2020 and March 2021. We aimed to understand how access to healthcare for these conditions was affected during the pandemic. The survey asked respondents to report their characteristics, access to healthcare for asthma and COPD, types of services they found disrupted and telehealth (telephone or video appointment) use during the pandemic. We analysed 433 responses and found that access to healthcare for asthma and COPD was lower during the pandemic than pre-pandemic (<i>p</i> < 0.001). Specialty care services were most frequently reported as disrupted, while primary care, home care and diagnostics were least disrupted. Multivariable logistic regression revealed that access during the pandemic was positively associated with self-assessed financial ability (OR = 22.0, 95% CI: 7.0 - 84.0, <i>p</i> < 0.001, reference is disagreeing with having financial ability) and living in medium-sized urban areas (OR = 2.3, 95% CI: 1.0 - 5.2, <i>p</i> = 0.04, reference is rural areas). These disparities in access should be validated post-pandemic to confirm whether they still persist. They also indicate the continued relevance of exploring approaches for more equitable healthcare.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"20 ","pages":"14799731231172518"},"PeriodicalIF":4.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/4e/10.1177_14799731231172518.PMC10184213.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. 短效毒蕈碱拮抗剂联合长效β -2激动剂治疗稳定型慢性阻塞性肺疾病患者的疗效和安全性:一项系统回顾和荟萃分析
IF 4.1 3区 医学
Chronic Respiratory Disease Pub Date : 2023-01-01 DOI: 10.1177/14799731231166008
Kazuya Tanimura, Susumu Sato, Yukio Fujita, Yoshifumi Yamamoto, Takashi Hajiro, Nobuyuki Horita, Tomotaka Kawayama, Shigeo Muro
{"title":"The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis.","authors":"Kazuya Tanimura,&nbsp;Susumu Sato,&nbsp;Yukio Fujita,&nbsp;Yoshifumi Yamamoto,&nbsp;Takashi Hajiro,&nbsp;Nobuyuki Horita,&nbsp;Tomotaka Kawayama,&nbsp;Shigeo Muro","doi":"10.1177/14799731231166008","DOIUrl":"https://doi.org/10.1177/14799731231166008","url":null,"abstract":"<p><strong>Background: </strong>The rationale for additional treatment with short-acting bronchodilators combined with long-acting bronchodilators for patients with chronic obstructive pulmonary disease (COPD) is not adequately studied.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of a short-acting muscarinic antagonist (SAMA) therapy combined with a long-acting beta-2 agonist (LABA) in patients with stable COPD. Pulmonary function, dyspnea, health-related quality of life, exercise tolerance, physical activity, exacerbations of COPD, and adverse events during regular use were set as outcomes of interest.</p><p><strong>Results: </strong>We included five controlled trials including two sets of publicly available online data without article publications for the meta-analysis. Additional use of SAMA plus LABA showed a significant improvement in the peak response in FEV<sub>1</sub> (mean difference (MD) 98.70 mL, <i>p</i> < .00001), transitional dyspnea index score (MD .85, <i>p</i> = .02), and St George's Respiratory Questionnaire score (MD -2.00, <i>p</i> = .008) compared to LABA treatment. There was no significant difference in the risk of exacerbation of COPD (<i>p</i> = .20) and only a slight trend of increased severe adverse events (OR: 2.16, <i>p</i> = .08) and cardiovascular events (OR: 2.38, <i>p</i> = .06).</p><p><strong>Conclusion: </strong>Additional treatment with SAMA combined with LABA could be a feasible choice due to its efficacy and safety.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"20 ","pages":"14799731231166008"},"PeriodicalIF":4.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/d6/10.1177_14799731231166008.PMC10052583.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9210724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Alterations in circulating mitochondrial signals at hospital admission for COPD exacerbation. 慢性阻塞性肺疾病恶化入院时循环线粒体信号的变化。
IF 4.1 3区 医学
Chronic Respiratory Disease Pub Date : 2023-01-01 DOI: 10.1177/14799731231220058
Carlos A Amado, Paula Martín-Audera, Juan Agüero, Diego Ferrer-Pargada, Begoña Josa Laorden, Daymara Boucle, Ana Berja, Bernardo A Lavín, Armando R Guerra, Cristina Ghadban, Pedro Muñoz, Mayte García-Unzueta
{"title":"Alterations in circulating mitochondrial signals at hospital admission for COPD exacerbation.","authors":"Carlos A Amado, Paula Martín-Audera, Juan Agüero, Diego Ferrer-Pargada, Begoña Josa Laorden, Daymara Boucle, Ana Berja, Bernardo A Lavín, Armando R Guerra, Cristina Ghadban, Pedro Muñoz, Mayte García-Unzueta","doi":"10.1177/14799731231220058","DOIUrl":"10.1177/14799731231220058","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) exacerbation (ECOPD) alters the natural course of the disease. To date, only C-reactive protein has been used as a biomarker in ECOPD, but it has important limitations. The mitochondria release peptides (Humanin (HN), FGF-21, GDF-15, MOTS-c and Romo1) under certain metabolic conditions. Here, we aimed to evaluate the pathophysiologic, diagnostic and prognostic value of measuring serum mitochondrial peptides at hospital admission in patients with ECOPD.</p><p><strong>Methods: </strong>A total of 51 consecutive patients admitted to our hospital for ECOPD were included and followed for 1 year; in addition, 160 participants with stable COPD from our out-patient clinic were recruited as controls.</p><p><strong>Results: </strong>Serum FGF-21 (<i>p</i> < .001), MOTS-c (<i>p</i> < .001) and Romo1 (<i>p</i> = .002) levels were lower, and GDF-15 (<i>p</i> < .001) levels were higher, in patients with ECOPD than stable COPD, but no differences were found in HN. In receiver operating characteristic analysis, MOTS-c (AUC 0.744, 95% CI 0.679-0.802, <i>p</i> < .001) and GDF-15 (AUC 0.735, 95% CI 0.670-0.793, <i>p</i> < .001) had the best diagnostic power for ECOPD, with a diagnostic accuracy similar to that of C-RP (AUC 0.796 95% IC 0.735-0.848, <i>p</i> < .001). FGF-21 (AUC 0.700, 95% CI 0.633-0.761, <i>p</i> < .001) and Romo1 (AUC 0.645 95% CI 0.573-0.712, <i>p</i> = .001) had lower diagnostic accuracy. HN levels did not differentiate patients with ECOPD versus stable COPD (<i>p</i> = .557). In Cox regression analysis, HN (HR 2.661, CI95% 1.009-7.016, <i>p</i> = .048) and MOTS-c (HR 3.441, CI95% 1.252-9.297, <i>p</i> = .016) levels exceeding mean levels were independent risk factors for re-admission.</p><p><strong>Conclusions: </strong>Most mitochondrial peptides are altered in ECOPD, as compared with stable COPD. MOTS-c and GDF15 levels have a diagnostic accuracy similar to C-RP for ECOPD. HN and MOTS-c independently predict future re-hospitalization.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"20 ","pages":"14799731231220058"},"PeriodicalIF":4.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10734331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138799454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Muscle oxygen utilization and ventilatory parameters during exercise in people with cystic fibrosis: Role of HbA1c. 囊性纤维化患者运动期间肌肉氧利用和通气参数:HbA1c的作用
IF 4.1 3区 医学
Chronic Respiratory Disease Pub Date : 2023-01-01 DOI: 10.1177/14799731231174542
Brooke P Quertermous, Nichole Seigler, Jacob Looney, Reva Crandall, Abigayle B Simon, Marsha Blackburn, Cassandra C Derella, Anson Blanks, Kathleen T McKie, Caralee Forseen, Ryan A Harris
{"title":"Muscle oxygen utilization and ventilatory parameters during exercise in people with cystic fibrosis: Role of HbA<sub>1c</sub>.","authors":"Brooke P Quertermous,&nbsp;Nichole Seigler,&nbsp;Jacob Looney,&nbsp;Reva Crandall,&nbsp;Abigayle B Simon,&nbsp;Marsha Blackburn,&nbsp;Cassandra C Derella,&nbsp;Anson Blanks,&nbsp;Kathleen T McKie,&nbsp;Caralee Forseen,&nbsp;Ryan A Harris","doi":"10.1177/14799731231174542","DOIUrl":"https://doi.org/10.1177/14799731231174542","url":null,"abstract":"<p><strong>Introduction: </strong>Glycated hemoglobin can interfere with oxygen delivery and CO<sub>2</sub> removal during exercise. Additionally, pancreatic insufficiency increases oxidative stress and exacerbates exercise intolerance in people with cystic fibrosis (PwCF). This investigation sought to test the hypotheses that elevated Hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) can negatively affect exercise parameters in PwCF and that reductions in oxidative stress can improve tissue oxygenation in individuals with elevated HbA<sub>1c</sub>.</p><p><strong>Methods: </strong>Twenty four PwCF were divided into two groups; normal HbA1c <5.7% (N-HbA<sub>1c</sub>) and elevated HbA<sub>1c</sub> >5.7% (E-HbA<sub>1c</sub>). A maximal exercise test was conducted to obtain peak oxygen uptake (VO<sub>2</sub>peak), VO<sub>2</sub> at ventilatory threshold (VT), ventilatory parameters (V<sub>E</sub>/VCO<sub>2</sub> slope and end-tidal CO<sub>2</sub> (petCO<sub>2</sub>)). Near-Infrared Spectroscopy (NIRS) was used to assess muscle oxygenated/deoxygenated hemoglobin during exercise. A subset of individuals with E-HbA<sub>1c</sub>were given an antioxidant cocktail (AOC) for 4 weeks to determine the effects on tissue oxygenation during exercise.</p><p><strong>Results: </strong>A negative relationship between HbA<sub>1c</sub> and VO<sub>2</sub>peak at VT was observed (r = -0.511; <i>p</i> = 0.018). In addition, a positive relationship between HbA<sub>1c</sub> and V<sub>E</sub>/VCO<sub>2</sub> slope (<i>r =</i> 0.587;<i>p</i> = 0.005) and a negative relationship between HbA<sub>1c</sub> and petCO<sub>2</sub> at maximal exercise (<i>r</i> = -0.472<i>;p =</i> 0.031) was observed. N-HbA<sub>1c</sub> had greater VO<sub>2</sub>peak (<i>p</i> = 0.021), VO<sub>2</sub> at VT (<i>p</i> = 0.004), petCO<sub>2</sub> (<i>p =</i> 0.002), and lower V<sub>E</sub>/VCO<sub>2</sub> slope (<i>p</i> = 0.004) compared with E-HbA<sub>1c</sub>. Muscle deoxygenated hemoglobin at VT was higher in N-HbA<sub>1c</sub> vs. E-HbA<sub>1c</sub> and 4 weeks of AOC improved skeletal muscle utilization of oxygen.</p><p><strong>Conclusion: </strong>Findings demonstrate that glycated hemoglobin may lead to tissue oxygenation impairment and ventilation inefficiency during exercise in PwCF. In addition, antioxidant supplementation may lead to improved tissue oxygenation during exercise.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"20 ","pages":"14799731231174542"},"PeriodicalIF":4.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/e3/10.1177_14799731231174542.PMC10184196.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9562038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age of asthma onset does not impact the response to omalizumab. 哮喘发病年龄不影响对奥玛珠单抗的反应。
IF 4.1 3区 医学
Chronic Respiratory Disease Pub Date : 2023-01-01 DOI: 10.1177/14799731231159673
Linda Rogers, Cecile Tj Holweg, Hooman Pazwash, Jinnie Ko, Samuel Louie
{"title":"Age of asthma onset does not impact the response to omalizumab.","authors":"Linda Rogers,&nbsp;Cecile Tj Holweg,&nbsp;Hooman Pazwash,&nbsp;Jinnie Ko,&nbsp;Samuel Louie","doi":"10.1177/14799731231159673","DOIUrl":"https://doi.org/10.1177/14799731231159673","url":null,"abstract":"<p><strong>Trial registration: </strong>These studies were conducted before clinical trial registration was required; therefore, clinical trial registration numbers are not available.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"20 ","pages":"14799731231159673"},"PeriodicalIF":4.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/a9/10.1177_14799731231159673.PMC10071096.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9305679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thanks to reviewers. 感谢评论者。
IF 4.1 3区 医学
Chronic Respiratory Disease Pub Date : 2023-01-01 DOI: 10.1177/14799731231158689
{"title":"Thanks to reviewers.","authors":"","doi":"10.1177/14799731231158689","DOIUrl":"https://doi.org/10.1177/14799731231158689","url":null,"abstract":"","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"20 ","pages":"14799731231158689"},"PeriodicalIF":4.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10765600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信